# ResectOvarAI - Ovarian Cancer Debulking Feasibility Platform

## Venture Spec

**Date:** 2026-03-02
**Status:** GO - 8.00/10
**Category:** Healthcare AI / Gynecologic Oncology / Surgical Planning

---

## Name

**ResectOvarAI - Ovarian Cancer Cytoreductive Feasibility Prediction**

---

## Core Concept

AI-powered platform for gynecologic oncologists that preoperatively predicts the feasibility of optimal cytoreductive surgery (R0 resection) in advanced ovarian cancer patients. Uses CT imaging + CA-125 + clinical factors to predict likelihood of complete tumor removal, guiding neoadjuvant chemotherapy (NACT) vs. primary debulking surgery (PDS) decisions and reducing non-therapeutic laparotomies.

---

## Problem Statement

### The Clinical Challenge

- **20,000+ ovarian cancer cases annually** in the United States
- **60% present at Stage III-IV** (advanced disease)
- **40-60% of explorations find unresectable disease** - non-therapeutic laparotomy
- **Non-therapeutic laparotomy = wasted surgery** - patient morbidity, no clinical benefit
- **Current prediction is crude:** CT assessment has 50-70% accuracy
- **No reliable pre-op decision tool** for NACT vs. PDS

### The Treatment Dilemma

```
Advanced Ovarian Cancer (Stage III-IV):

Option A: Primary Debulking Surgery (PDS)
- Goal: R0 resection (no visible disease)
- Benefit: Immediate cytoreduction
- Risk: 40-60% find unresectable disease (wasted surgery)

Option B: Neoadjuvant Chemotherapy (NACT) → Interval Debulking
- Benefit: Shrink tumor, higher resection rate
- Risk: Delay surgery, potential chemoresistance

Problem: No reliable way to predict which patients will achieve R0 upfront.
```

### The Patient Impact

```
"She underwent a 4-hour surgery, only to find disseminated disease
throughout the diaphragm and liver surface. We closed her without
resecting anything. Now she needs 3 cycles of chemo before we can
try again. She lost 30 pounds and missed 2 months of work."
- Gynecologic Oncologist
```

### The Economic Burden

- **Non-therapeutic laparotomy cost:** $30,000-$50,000 per case
- **Morbidity cost:** ICU stay, wound complications, delayed chemo
- **Hospital resource utilization:** OR time, surgical team
- **Malpractice risk:** "Unnecessary surgery" claims

---

## Target Vertical

### Primary: Gynecologic Oncology

| Role | Pain Points | Decision Maker |
|------|-------------|----------------|
| Gynecologic Oncologists | Non-therapeutic laparotomies, NACT vs PDS decisions | Primary User |
| Gyn Onc Fellows | Surgical planning, learning curve | Primary User |

### Secondary: Hospital Administration

| Role | Pain Points | Decision Maker |
|------|-------------|----------------|
| Hospital C-Suite | OR utilization, surgical costs | Budget Approver |
| Quality/Safety Officers | Surgical morbidity, ovarian cancer mortality | Champion |
| Tumor Boards | Treatment planning decisions | Champion |

---

## Why Now

### 1. Clinical Evidence

- **NACT proven equivalent** for selected patients (EORTC 55971, CHORUS trials)
- **Patient selection is critical** - need better tools to identify NACT candidates
- **CT imaging is standard** - all patients have pre-op CT
- **Retrospective data available** - CT + outcomes correlation exists

### 2. Technology Readiness

- **Peritoneal disease detection CV** is feasible (multiple research papers)
- **Radiomics features** correlate with resectability
- **Multi-modal AI** (CT + biomarkers + clinical data) improves prediction
- **Cloud PACS integration** is mature

### 3. Regulatory Tailwinds

- **SaMD Class II pathway** - clinical decision support (moderate risk)
- **NCCN guidelines** endorse NACT for selected patients (need better selection)
- **Quality metrics** - hospitals track ovarian cancer suboptimal debulking rates

### 4. Market Concentration

- **1,200 gyn oncs concentrated** in academic centers and high-volume practices
- **High-volume centers** have 50+ ovarian cancer cases/year
- **Tumor board infrastructure** exists for decision support adoption

---

## AI Advantage

### Core Capabilities

| Capability | Technology | Clinical Impact |
|------------|------------|-----------------|
| **Peritoneal Carcinomatosis Detection** | Computer vision on CT | Identify diaphragmatic, mesenteric, liver surface disease |
| **Resectability Prediction** | Multi-modal ML (CT + CA-125 + clinical) | Predict likelihood of R0 resection |
| **NACT Recommendation** | Risk stratification model | Guide NACT vs. PDS decision |
| **Surgical Planning Report** | Structured output with visualization | Pre-op briefing, tumor board presentation |
| **Outcome Tracking** | Prospective validation integration | Learning system, model improvement |

### Technical Differentiation

```
Current Standard of Care:
- Radiologist CT read (subjective, variable)
- Surgeon "gut feeling" based on CT review
- Laparoscopic assessment (invasive, adds procedure)
- 50-70% accuracy for resectability prediction

ResectOvarAI:
- Automated peritoneal disease detection
- Multi-modal prediction (CT + CA-125 + clinical factors)
- Quantitative resectability score (0-100)
- Evidence-based NACT recommendation
- Prospective learning system
```

### Detection Targets

| Disease Site | Detection Method | Resectability Impact |
|--------------|------------------|---------------------|
| **Diaphragmatic** | CT upper abdomen, right/left hemidiaphragm | High impact (hard to resect) |
| **Mesenteric** | Small bowel mesentery, root of mesentery | High impact (resection contraindication) |
| **Liver Surface** | Glisson's capsule, superficial lesions | Moderate impact (resectable) |
| **Omental** | Omentum, omental cake | Low impact (easily resected) |
| **Parenchymal** | Liver parenchyma metastases | Moderate impact (requires resection) |

---

## Viral Mechanism

### Conference Strategy

- **SGO (Society of Gynecologic Oncology)** - 1,500+ attendees, annual meeting
- **IGCS (International Gynecologic Cancer Society)** - Global audience
- **ESGO (European Society of Gynecological Oncology)** - European market entry

### Viral Messaging

> "AI predicted unresectable disease. Patient got NACT instead of wasted surgery. Now disease-free after interval debulking."
>
> "Our non-therapeutic laparotomy rate dropped from 45% to 15% with AI-guided patient selection."

### Case Study Format

- **Patient Story:** Specific patient spared unnecessary surgery
- **Before/After:** Non-therapeutic laparotomy rate reduction
- **Quality Improvement:** Hospital metrics improvement
- **Cost Savings:** OR utilization, surgical costs

### Academic Validation

- **Gynecologic Oncology** - Primary publication target
- **Annals of Surgical Oncology** - Surgical outcomes focus
- **ASCO abstracts** - Clinical trial integration
- **NCCN guidelines** - Future inclusion potential

---

## Revenue Model

### Pricing Model

Given the small but concentrated market (1,200 gyn oncs), pricing is **high-ARPU, practice-based**:

| Tier | Annual Price | Features | Target |
|------|--------------|----------|--------|
| **Academic** | $150,000/year | Full suite + research collaboration + API access + custom models | Academic medical centers |
| **High-Volume Practice** | $100,000/year | Full suite + tumor board integration + outcome tracking | Large private practices |
| **Standard Practice** | $50,000/year | Resectability prediction + NACT recommendation | Community practices |

### Per-Case Add-On

- **$500 per AI-assisted case** for high-volume practices beyond included tiers
- **Bundled pricing** for hospital-wide deployment

### Unit Economics

| Metric | Value | Notes |
|--------|-------|-------|
| **CAC** | $25,000 | SGO conferences, direct sales |
| **ARPU** | $100,000 | Academic tier average |
| **LTV** | $300,000 | 36-month retention (very high switching costs) |
| **Gross Margin** | 80% | Software, clinical support costs |
| **LTV:CAC** | 12:1 | Strong unit economics |

### Sales Cycle

- **Pilot:** 6-8 weeks (retrospective validation, prospective trial)
- **Implementation:** 2-4 weeks (PACS integration, tumor board workflow)
- **Contract:** 12-36 month commitments (annual recurring)

---

## MVP in 8 Weeks

### Weeks 1-2: Data & Partnership

**Goal:** Secure one gyn onc partnership, collect ovarian cancer CT data

- Identify and pitch one academic gyn onc practice (high-volume ovarian cancer)
- IRB approval for retrospective data analysis
- Extract pre-op CTs + surgical outcomes for 150+ ovarian cancer cases
- Define data schema (CT features, CA-125, surgical outcomes)

**Deliverable:** De-identified ovarian cancer dataset

### Weeks 3-5: Model Development

**Goal:** Build resectability prediction ML with >0.75 AUC

- Feature engineering:
  - CT: Peritoneal disease detection, diaphragmatic involvement, liver surface
  - Biomarkers: CA-125, HE4
  - Clinical: Age, performance status, comorbidities
- Model training (XGBoost, multimodal fusion)
- Validation with time-based cross-validation
- Calibration for clinical interpretability

**Deliverable:** Trained resectability model with performance report

**Validation Metrics:**
- AUC-ROC > 0.75 for predicting R0 resection
- Sensitivity > 0.70 (identify resectable)
- Specificity > 0.70 (identify unresectable)
- Calibration error < 0.15

### Weeks 6-7: Pilot & Validation

**Goal:** One practice pilot, validate against surgical outcomes

- Deploy model on practice's historical cases
- Compare AI predictions vs. actual surgical outcomes
- Measure NACT recommendation accuracy
- Gather surgeon feedback on UI/UX

**Deliverable:** Pilot validation report with case studies

**Pilot Metrics:**
- Correct NACT recommendation in >75% of cases
- Non-therapeutic laparotomy reduction vs. baseline
- Surgeon adoption satisfaction > 4/5

### Week 8: Refinement & Demo

**Goal:** Refine model, prepare SGO conference demo

- Model refinement based on pilot feedback
- Build demo interface for conference presentation
- Create case study materials ("Patient Spared Surgery")
- Prepare SGO abstract submission

**Deliverable:** Conference-ready demo + 2-3 case studies

---

## Tech Stack

### Backend & AI

```
Language: Python 3.11+
Framework: FastAPI
AI/ML: Scikit-learn, XGBoost, PyTorch
Medical Imaging: MONAI, PyTorch Medical, SimpleITK
Data: Pandas, NumPy
```

### Integrations

```
PACS Systems:
- All major PACS (DICOM standard)

EHR Systems:
- Epic (FHIR API for CA-125, clinical data)
- Cerner (FHIR)

Biomarker Labs:
- Lab information systems (CA-125, HE4 integration)
```

### Infrastructure

```
Cloud: AWS (us-east-1)
Compute: ECS Fargate (HIPAA compliant)
Storage: S3 (encrypted, DICOM storage)
Database: PostgreSQL (RDS encrypted)
Monitoring: CloudWatch, Datadog
Security: VPC, encryption at rest/transit, audit logs
```

### Compliance

```
HIPAA: BAA with all vendors
SOC 2: Type II certification (planned Year 2)
FDA: SaMD Class II pathway (clinical decision support)
```

---

## Market Opportunity

### Market Size

| Segment | Estimate | Notes |
|---------|----------|-------|
| US Gynecologic Oncologists | 1,200 | Highly concentrated |
| Academic Medical Centers | 50-75 | High-volume, ideal targets |
| High-Volume Private Practices | 100-150 | Secondary targets |
| Community Practices | 800+ | Tertiary market |

### Revenue Potential

- **TAM:** 1,200 gyn oncs × $100,000 = $120M ARR
- **SAM:** 200 academic/high-volume practices = $20M ARR
- **SOM (3-year):** 20 practices = $2M ARR

### International Expansion

- **Europe:** ESGO market, similar incidence
- **Japan:** High ovarian cancer incidence, advanced imaging
- **Australia:** Developed gyn onc market

---

## Competitive Threat

### Direct Competitors

| Competitor | Strengths | Weaknesses |
|------------|-----------|------------|
| **Radiology AI (general)** | Peritoneal disease detection | Not focused on resectability, no clinical integration |
| **Olympus (surgical)** | OR integration, visualization | No prediction capability |
| **Intuitive Surgical (da Vinci)** | Robotic platforms | Not focused on prediction, procedural focus |
| **Academic tools** | Research prototypes | Not commercialized, no support |

### Differentiation Strategy

**ResectOvarAI is the only platform with:**

1. **Ovarian-specific resectability ML** - Focused on advanced ovarian cancer
2. **Multi-modal prediction** - CT + biomarkers + clinical factors
3. **NACT decision support** - Evidence-based treatment guidance
4. **Prospective learning** - Outcome tracking improves model
5. **Tumor board integration** - Designed for gyn onc workflow

**Competitive moat:**
- **Specialized clinical knowledge** - Requires gyn onc expertise
- **Outcome data linkage** - Surgical outcomes are practice-specific
- **Small market concentration** - Easy to cover entire market
- **Academic partnerships** - Research collaborations create barriers

---

## Risk Factors

### Clinical Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **False Negatives** | Recommend NACT when resection possible | High sensitivity calibration, surgeon-in-the-loop |
| **False Positives** | Recommend surgery when unresectable | Conservative specificity, transparent uncertainty |
| **Model Drift** | Performance changes over time | Continuous monitoring, retraining |
| **CT variability** | Different scanners, protocols | Normalization, multi-site training |

### Commercial Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **Very small market** | 1,200 gyn oncs total | High ARPU, rapid market saturation |
| **Slow adoption** | Conservative surgeons | Academic KOLs, pilot validation |
| **PACS integration** - Healthcare IT delays | Start with DICOM export, cloud |
| **Reimbursement uncertainty** - No CPT code | Practice-funded, cost savings narrative |

### Regulatory Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **FDA SaMD requirements** | Expensive pathway | CDS pathway (lower risk), IDE preparation |
| **Liability exposure** | Wrong NACT recommendation | Clear disclaimers, surgeon decision |
| **HIPAA compliance** | Breach penalties | Security-first architecture |

---

## Go/No-Go Decision

### Score: 8.00/10 - **GO**

### Strengths

- **Highest pain score (10)** - Non-therapeutic laparotomy is devastating
- **Strong defensibility (9)** - Requires gyn onc expertise + outcome data
- **High AI-native (8)** - Multi-modal ML, not GPT wrapper
- **Clear clinical value** - Reduces morbidity, saves costs
- **Concentrated market** - 1,200 gyn oncs in academic centers

### Weaknesses

- **Smallest market ever pursued** - 1,200 gyn oncs (vs. 5K+ for most ideas)
- **Long validation timeline** - Need surgical outcome correlation
- **Limited expansion** - Gyn onc is niche subspecialty

### Why This Scores 8.00

Despite the smallest market, this venture scores 8.0 because:

1. **Highest pain score (10)** - Non-therapeutic laparotomy causes patient harm, unnecessary morbidity
2. **Mortality urgency** - Ovarian cancer has high mortality (30% 5-year survival for Stage III-IV)
3. **Avoidance value** - Preventing unnecessary surgery is compelling
4. **High ARPU** - $100K/practice compensates for small market
5. **Concentration** - Academic centers with volume create efficient sales

**Market size is compensated by:**
- Extreme concentration (50 academic centers do 60% of cases)
- High willingness-to-pay (morbidity prevention)
- Low competitive threat (radiology AI doesn't focus here)
- Fast market saturation potential (entire addressable market = 200 practices)

---

## Critical Success Factors

### 1. Gynecologic Oncology Leadership

- **Hire gyn onc surgeons** as co-founders or advisors (non-negotiable)
- **Build medical advisory board** with ovarian cancer specialists
- **Understand NACT vs. PDS dilemma** deeply

### 2. Academic Partnerships

- **Partner with academic medical centers** (high volume, research interest)
- **Focus on top 20 ovarian cancer centers** (they do 50% of cases)
- **Build research collaborations** for publication and validation

### 3. Multi-Modal Approach

- **CT alone is insufficient** - must include CA-125, clinical factors
- **Biomarker integration** is key differentiator
- **Clinical workflow integration** - tumor board presentation

### 4. Evidence Generation

- **Prospective validation trial** - required for adoption
- **Publication strategy** - Gynecologic Oncology, Annals Surg Onc
- **NCCN guideline inclusion** - long-term goal

### 5. Conference Presence

- **SGO Annual Meeting** - primary venue
- **IGCS, ESGO** - international expansion
- **Tumor board integration** - workflow adoption

---

## Next Steps

### Immediate (Week 1)

1. **Form gyn onc advisory board** - Recruit 2-3 gyn oncologists
2. **Identify academic partner** - High-volume ovarian cancer center
3. **Draft IRB protocol** - For retrospective data access
4. **Design data schema** - CT features, biomarkers, outcomes

### Short-term (Month 1-2)

1. **Secure first academic partnership** - Sign data agreement
2. **Extract and validate dataset** - 150+ ovarian cancer cases
3. **Train initial model** - Target >0.75 AUC
4. **Build retrospective tool** - Batch processing

### Medium-term (Month 3-4)

1. **Run pilot validation** - Measure NACT recommendation accuracy
2. **Build tumor board UI** - Surgical planning report
3. **Gather feedback** - Iterate on surgeon workflow
4. **Prepare SGO abstract** - Conference submission

### Long-term (Month 5-8)

1. **Convert pilot to customer** - First academic contract
2. **Build sales collateral** - Case studies, cost savings calculator
3. **Hire sales leader** - Healthcare IT, oncology focus
4. **Scale to 5-10 centers** - Reference customer base

---

## Conclusion

**Non-therapeutic laparotomy + ovarian cancer mortality + AI prediction = life-saving urgency.**

ResectOvarAI addresses one of the most devastating problems in gynecologic oncology:

- **Non-therapeutic laparotomy** causes patient harm, morbidity, delayed treatment
- **40-60% of explorations find unresectable disease** - massive clinical failure
- **AI prediction** can guide NACT vs. PDS decisions, reducing failed surgeries

The 8.00/10 score reflects the exceptional clinical urgency, strong AI approach, and concentrated market despite the small size. While the market (1,200 gyn oncs) is the smallest ever pursued, the high ARPU ($100K), concentration (academic centers), and avoidance value (preventing unnecessary surgery) compensate.

**Go build ResectOvarAI. Patients are undergoing unnecessary surgeries.**

---

*Venture Spec Generated: 2026-03-02*
*Status: GO - 8.00/10*
